Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

GE HealthCare aims to advance a new era in theranostics with StarGuide™ GX 4D SPECT ...

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at gehealthcare.com →

◆ Verified

Fusion42 · 9 September 2026 · Fusion42 review

GE HealthCare has a novel theranostics imaging device, the StarGuide GX 4D SPECT/CT, currently pending 510(k) FDA clearance in the United States, signalling advancement in theranostics diagnostics technology.

This Wire brief sits within Fusion42's coverage of Medtech, and 1 source has reported it.

◆ ◆ The Wire takeaway

Theranostics device makers now face a clear pathway for US market entry with GE HealthCare pushing 510(k) clearance for StarGuide GX 4D SPECT/CT. You should prepare your regulatory and commercial strategy with this regulatory development in mind.

◆ Coverage

1 source · 8 Sep 2026

◆ Related on Wire

◆ Topics

Medtechtheranosticsmedical-imagingFDA-clearancehealthcare-innovation